SIGLEC9 triggered a signal that led to the degradation of focal adhesion kinase (FAK), associated in a great manner with PI3K-Akt signaling, in tumor cells through an interaction between SIGLEC9 on immune cells and its coreceptors on tumor cells via sialylglycoconjugates, leading to modulation of tumor cell adhesion kinetics. Here, PTK2 is linked to neoplasm.